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Historically, exposure science has taught us how individuals can prevent transmission of infections using such simple measures as properly washing hands and coughing into one's sleeve, and it has also been used for evaluating exposure to infectious diseases. More current exposure science enables early detection of novel influenza viruses, which is critical in controlling rapid and widespread infection that could result in heightened morbidity and mortality and overwhelm health-care systems. A new H1N1 influenza virus (see figure) that emerged in Mexico was first detected in California in mid-April of 2009. Laboratory testing at the Centers for Disease Control and Prevention confirmed that this virus had not previously been detected in humans. Exposure science could be applied to improve future flu vaccines.
Early detection of novel influenza viruses can enable interventions to reduce their transmission, thereby reducing morbidity and mortality through deployment of antivirals and vaccines. There was no known connection between the two patients and no exposure to pigs. Laboratory analysis at the CDC determined that the viruses obtained from these two patients were almost identical to each other and different from any influenza virus previously seen in either humans or animals. Testing showed that these two viruses were resistant to certain influenza antiviral drugs (called M2 ion channel inhibitors) but susceptible to a class of antiviral drugs called neuraminidase inhibitors.
Infection with a new swine-origin influenza virus in two patients living 130 miles apart raised concern that a novel swine-origin influenza virus had made its way into the human population and was spreading. There had previously been sporadic reports of human infection with North American-lineage swine influenza viruses in the United States, most often associated with close contact with infected pigs. However, human-to-human spread of swine influenza viruses is rare, and these viruses had not caused large community, regional, or global outbreaks. In June 2009, the World Health Organization declared that the novel 2009 H1N1 viruses were causing a pandemic. By the end of 2009, an estimated 57 million people worldwide had been infected with 2009 H1N1, and over 14,000 people had died (Bell et al. 2009; Reed et al., 2009) . Within the United States alone, 22 million had contracted the disease, resulting in about 4,000 deaths, including those of 500 children (Reed et al., 2009 ).
IMPACT AND IMPLICATIONS FOR EXPOSURE SCIENCE
Early detection and identification of emerging influenza viruses are critical for the implementation of appropriate public health interventions. In addition, identification of variant viruses is crucial for the selection of seasonal influenza viruses to be included in the influenza vaccines that are necessary to prevent influenza epidemics and pandemics. Exposure science plays an essential role in both efforts. Several laboratory diagnostic tests can be used to detect the presence of influenza viruses in respiratory specimens (Boggild and McGeer, 2010) . However, these tests differ in their sensitivity and specificity in detecting influenza viruses as well as in their commercial availability, the amount of time needed between specimen collection and availability of results, and their ability to distinguish between different influenza virus types (A versus B) and influenza A subtypes (e.g., novel H1N1 versus other seasonal H3N2 viruses). Blood tests can help to establish a diagnosis of influenza virus infection for research studies, but such testing is not routinely available through clinical laboratories. More advanced methods were rapidly developed for diagnosis of 2009 pandemic influenza H1N1 viruses. Further characterization of novel influenza 2009 H1N1 infection may be necessary for surveillance purposes and for special situations, e.g., for analyzing specimens from severely ill patients and immunocompromised patients.
Seasonal influenza vaccines typically include three influenza viruses selected on the basis of early evaluation of the antigenic and genetic characteristics of viruses circulating globally. The vaccine manufacturing process takes approximately 6-8 months, and vaccination campaigns now require about 3 months to complete. Hence, the predictions of variant viruses must be made nearly one year prior to the deployment of the vaccine, occasionally leading to a suboptimal antigenic match between circulating viruses and vaccine antigens. Most of the evaluation process of the vaccine involves laborious and time-consuming laboratory and animal studies. The techniques to standardize the amount of a critical component (hemagglutinin) in vaccines are slow and imprecise, causing sporadic delays in the vaccine production process. A new laboratory technique based on mass spectrometry has been developed that could significantly shorten some of these testing steps and accelerate the delivery of a vaccine to the population. Shortening the time required for production and testing of the influenza vaccines would potentially enable the selection of candidate viruses for updating the composition of vaccines to be made closer to the time of vaccination, allowing for more accurate selection of the appropriate vaccine viruses. This new science could be applied to the development of the seasonal influenza virus vaccines, to ensure that they are highly effective. To summarize:
• Early detection and isolation of novel influenza viruses can allow implementation of control measures to delay widespread transmission and ultimately reduce morbidity and mortality.
• Exposure science helps in the accurate identification of new influenza strains.
• Using exposure science to detect variant seasonal influenza strains early will facilitate production of more efficacious influenza vaccines.
